2017


To access this material please log in or register

Register Authorize
2017/№1

Doctor's attitude to administration of statins for primary prevention of cardiovascular diseases

Perepech N. B., Tregubov A. V.
Federal State Budgetary Educational Institution of Higher Education "Saint-Petersburg State University ", 7/9 University Embankment, St.-Petersburg, 199034

Keywords: primary prevention CVD, dyslipidemia, statins, drug safety, doctor's passivity

DOI: 10.18087/rhj.2017.1.2301

Background. Control of cardiovascular diseases (CVD) is a complicated and multicomponent task, the accomplishment of which largely depends on efficacy of primary prevention. Healthcare professionals play an important role in this process. Aim. To elucidate the doctor’s attitude to major aspects of CVD primary prevention with statins and to check doctors’ awareness of fundamental aspects of CVD primary prevention with statins based on actual Russian guidelines on diagnostics and treatment of lipid metabolic disorders for prevention and treatment of atherosclerosis. Materials and methods. Anonymous survey of 198 doctors, mostly physicians and cardiologists. Results. Most of the doctors had right notions of indications for using statins for primary prevention of CVD and criteria for efficacy of lipid-lowering therapy. More than 75% and 35% of respondents had wrong ideas of creatine kinase and transaminase critical levels, respectively, which are considered the criteria for termination of the statin treatment. Conclusion. Cardiologists were more aware than physicians of major principles for the statin treatment; however, cardiologists were excessively concerned about the risk of statin side effects and were prone to stop the statin treatment when creatine kinase and transaminase activities increase to levels not exceeding the critical value.
  1. Вишневский А., Андреев Е., Тимонин С. Смертность от болезней системы кровообращения и продолжительность жизни в России. Демографическое обозрение. 2016;3 (1):6–34 [Vishnevskij A., Andreev E., Timonin S. Smertnost` ot boleznej sistemy` krovoobrashheniya i prodolzhitel`nost` zhizni v Rossii. Demograficheskoe obozrenie. 2016;3 (1):6–34].
  2. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007 Oct;28 (19):2375–414.
  3. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). Атеросклероз и дислипидемии. 2012;4:5–52 [Diagnostika i korrekcziya narushenij lipidnogo obmena s czel`yu profilaktiki i lecheniya ateroskleroza. Rossijskie rekomendaczii (V peresmotr). Ateroskleroz i dislipidemii. 2012;4:5–52].
  4. Сергеева В.А. Трехлетняя динамика и неразрешенные проблемы гиполипидемической терапии. Рациональная фармакотерапия в кардиологии. 2015;11 (5):504–9 [Sergeeva V.A. Trexletnyaya dinamika i nerazreshenny`e problemy` gipolipidemicheskoj terapii. Raczional`naya farmakoterapiya v kardiologii. 2015;11 (5):504–9].
  5. Боева О.И., Иваненко А.С., Колесников В.Н., Байкулова М.Х. Приверженность к терапии статинами в реальной клинической практике. Медицинский вестник Северного Кавказа. 2010;18 (2):26–9 [Boeva O.I., Ivanenko A.S., Kolesnikov V.N., Bajkulova M.X. Priverzhennost` k terapii statinami v real`noj klinicheskoj praktike. Mediczinskij vestnik Severnogo Kavkaza. 2010;18 (2):26–9].
  6. Конради А.О., Полуничева Е.В. Недостаточная приверженность лечению артериальной гипертонии: причины и пути коррекции. Артериальная гипертензия. 2004;10 (3):137–43 [Konradi A.O., Polunicheva E.V. Nedostatochnaya priverzhennost` lecheniyu arterial`noj gipertonii: prichiny` i puti korrekczii. Arterial`naya gipertenziya. 2004;10 (3):137–43].
  7. Chobanian AV, Bakris GL, Black HR , Cushman WC, Green LA, Izzo JL et al. Seven report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42 (6):1206–52.
  8. Минаков Э.В., Хохлов Р.А., Фурменко Г.И., Ахмеджанов Н.М. Клиническая инертность как фактор, препятствующий эффективному лечению сердечно-сосудистых заболеваний. Рациональная фармакотерапия в кардиологии. 2009;5 (2):39–48 [Minakov E`.V., Xoxlov R.A., Furmenko G.I., Axmedzhanov N.M. Klinicheskaya inertnost` kak faktor, prepyatstvuyushhij e`ffektivnomu lecheniyu serdechno-sosudisty`x zabolevanij. Raczional`naya farmakoterapiya v kardiologii. 2009;5 (2):39–48].
  9. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL et al. Clinical inertia. Ann Intern Med. 2001 Nov 6;135 (9):825–34.
  10. Марцевич С.Ю., Кутишенко Н.П. Первичная профилактика сердечно-сосудистых осложнений: роль статинов. Рациональная фармакотерапия в кардиологии. 2009;5 (4):80–4 [Marczevich S.Yu., Kutishenko N.P. Pervichnaya profilaktika serdechno-sosudisty`x oslozhnenij: rol` statinov. Raczional`naya farmakoterapiya v kardiologii. 2009;5 (4):80–4].
  11. Goodman SG, Langer A, Bastien NR , McPherson R , Francis GA, Genest JJ, Leiter LA. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol. 2010 Nov;26 (9):e330–5.
Perepech N.B., Tregubov A.V. Doctor’s attitude to administration of statins for primary prevention of cardiovascular diseases. Russian Heart Journal. 2017;16 (1):52–58.

To access this material please log in or register

Register Authorize
Ru En